1. At a Glance – Blink and You’ll Miss the Punch
Gland Pharma is that introvert topper in class who doesn’t talk much but keeps topping exams. CMP at ₹1,690, market cap ₹27,848 Cr, Q3 FY26 sales ₹1,695 Cr (+22% YoY), and quarterly PAT ₹261 Cr (+36% YoY). Stock is down ~11% in 3 months, which tells you one thing clearly – market ka mood thoda bipolar hai. Despite a ROCE of just 11.9% and ROE of 7.8%, the company quietly throws off cash, stays nearly debt-free (D/E 0.03), and keeps launching complex injectables like it’s a Netflix series. Dividend yield at ~1.07% adds thoda emotional support. Valuation at ~32x P/E isn’t cheap-cheap, but this isn’t a momo FMCG stock either. Latest quarterly margins bounced back to 26% OPM. Question is simple: is Gland Pharma done disappointing, or just warming up?
2. Introduction – From COVID Hero to Market’s “Meh” Phase
Once upon a pandemic, Gland Pharma was the darling of Dalal Street. High margins, injectables boom, US exposure – sab kuch perfect lag raha tha. Then came post-COVID normalization, pricing pressure in the US, and the Cenexi acquisition, which dragged reported margins down from a spicy 34% in FY22 to a more sober 24% in FY24.
But markets have a short memory and even shorter patience. While stock returns over 5 years are negative (~-4.4%), the business hasn’t exactly collapsed. Revenue TTM stands at ₹6,113 Cr, PAT ₹847 Cr, and Q3 FY26 showed that growth hasn’t packed its bags and left.
So what are we looking at here? A structurally broken injectable story? Or a classic case of “market got bored, fundamentals didn’t”? Let’s open the books and do proper post-mortem.
3. Business Model – WTF Do They Even Do?
Gland Pharma is not your neighborhood pharma salesman pushing cough syrup. This is hardcore B2B injectable manufacturing.
